Mara Horwitz

Mara Horwitz is an endocrinologist specializing in calcium metabolism disorders including hypercalcemia of malignancy, a metabolic emergency affecting up to 20-30% of patients with advanced cancers. Her clinical research has evaluated denosumab and other RANK/RANKL-targeting agents for hypercalcemia refractory to bisphosphonates. She has studied the spectrum of PTHrP-driven and non-PTHrP-mediated hypercalcemia mechanisms and developed evidence-based management protocols. Her work bridges endocrinology and oncology in managing this common and life-threatening complication.